U.S. Markets closed

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.6000-0.0700 (-2.62%)
At close: 3:59PM EST

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660
United States
360 980 8524
http://www.cytodyn.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Dr. Scott A. KellyChairman, Chief Medical Officer & Head of Bus. Devel.208.22kN/A1970
Dr. Nader Z. PourhassanCEO, Pres & Director1.53MN/A1963
Mr. Michael D. Mulholland CPA, CPAChief Financial Officer445.43kN/A1952
Dr. Nitya G. RayCTO and Head of Process Sciences, Manufacturing & Supply Chain563kN/A1953
Dr. Mahboob U. Rahman FACR, M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Arian ColachisVP, Gen. Counsel & Sec.N/AN/A1962
Dr. Brendan P. RaeSr. VP of Bus. Devel.N/AN/AN/A
Mr. George BitarHead of Quality & Exec. DirectorN/AN/AN/A
Mr. Brian BrothenSr. VP of Global OncologyN/AN/AN/A
Dr. Denis R. BurgerScientific ConsultantN/AN/A1944
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Corporate Governance

CytoDyn Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.